2020-2027 Analysis and Review Aclidinium Bromide Market

Aclidinium Bromide Market

Aclidinium Bromide Market By Formulation (Aclidinium Bromide 400mcg/Actuation, Aclidinium Bromide 400mcg + Formoterol Fumarate 12mcg/Actuation), By End User (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

20-02-2020 REP-HC-5037 40 Tables 121 pages Format

The aclidinium bromide market was valued at USD1,052.9 Mn by 2019. According to the research findings brought forward by the World Health Organization (WHO), approximately 64 million people are affected with chronic obstructive pulmonary disorder throughout the globe. Rising prevalence of COPD and technological advancement in the aclidinium bromide inhaler formulation together drive the aclidinium bromide market growth.

 Aclidinium Bromide Market

Aclidinium bromide is an inhalation dry powder that is used for long term maintenance treatment of bronchospasm associated with COPD. It is basically a long-acting reversible anticholinergic agent that specifically binds to the M3 receptor to promote bronchodilation and facilitate breathing in COPD patients.

The major segments related to the aclidinium bromide market are:

By Formulation (2017–2027; US$ Mn)

Aclidinium Bromide 400mcg/Actuation

Aclidinium Bromide 400mcg + Formoterol Fumarate 12mcg/Actuation

By End User (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global aclidinium bromide market
  • The overall segmentation of the aclidinium bromide market, by formulation, end-user and geography is minutely studied. Aclidinium Bromide 400mcg/Actuationand hospital pharmacy are dominating the formulation and end-user segments respectively
  • Rising prevalence of chronic obstructive pulmonary disease (COPD) such as emphysema and chronic bronchitis primarily drive the aclidinium bromide market growth
  • Technological advancement in the formulation and development has led to dose fortification of aclidinium bromide with other drugs for effective COPD treatment 

Report gist?

  • The study of the global aclidinium bromide market includes qualitative analysis of factors such as drivers, restraints and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of formulation and end-user and categorization of the same at geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in the manufacturing and marketing of aclidinium bromide which is gaining huge demand owing to the rising prevalence of COPD worldwide
  • The report will benefit hospital pharmacist engaged in adjusting the inhaler dose of aclidinium bromide for the treatment of COPD patients
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to aclidinium bromide market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Aclidinium Bromide 400mcg/Actuation is ruling the formulation segment for the aclidinium bromide market. It gained USFDA clearance in 2012 for the long term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disorder (COPD). The recommended dose is 400mcg/actuation twice daily usually available in a multi-dose device as a dry powder inhaler which is metering 400mcg of aclidinium bromide per actuation. The combination formulation of Aclidinium Bromide 400mcg + Formoterol Fumarate 12mcg/Actuation is set to witness magnificent market growth in the near future on account of its ability to relieve the symptoms associated with COPD. The observation as reported from the clinical trial studies ensure that it reduces major cardiovascular adverse effects by 22% in comparison to aclidinium bromide as a single formulation.

Hospital pharmacy is representing the largest market share in the end-user segment for aclidinium bromide market. The inherent feature which is responsible for its market dominance is the availability of skilled pharmacist to compound aclidinium bromide inhaler dose precisely to negate any possible outcome of fatal overdose toxicity. Retail pharmacy is anticipated to register rapid market growth during the forecast period owing to the provision of aclidinium bromide formulation at an affordable price to ailing patients in the developing regions.

North America is presently dominating the geography segment for aclidinium bromide market. As per the statistics provided by the Center for Disease Control and Prevention (CDC), approximately 16 million U.S. citizens are suffering from chronic obstructive pulmonary disorder. Affordable reimbursement scenario pertaining to aclidinium bromide formulations and domicile of key players such as AstraZeneca, AB., Circassia Pharmaceuticals, Inc., Allergan, Plc., etc further consolidate the aclidinium bromide market growth in the region. Europe is currently in the 2nd place in the geography segment for aclidinium bromide market. The supportive regulatory environment provided by the European Medical Agency (EMA) for the formulation and sale of aclidinium bromide determines its market growth in the region. Asia Pacific is expected to register faster market growth in the near future owing to lucrative market opportunities for western giants to establish retail outlets and subsidiaries in the region for the sale and distribution of aclidinium bromide formulation. Additionally, a significant rise in air pollution and smoking has led to a constant increase in the number of patients suffering from emphysema and chronic bronchitis in the Asia Pacific.

Select License Type

$4,600
$6,600
$9,500

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.